IQVIA Holdings's ROE % for the quarter that ended in Mar. 2026 was 17.34%. IQVIA Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 4.55.
IQVIA Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.81%.
IQVIA Holdings ROE % Adjusted to Book Value Related Terms
IQVIA Holdings ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QTS vs WAT, ILMN, NTRA: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 3.81% mean?
IQVIA Holdings (FRA:QTS) has a ROE % Adjusted to Book Value of 3.81% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IQVIA Holdings and its competitors.
Is IQVIA Holdings' ROE % Adjusted to Book Value too high?
IQVIA Holdings' current ROE % Adjusted to Book Value is 3.81%. Overall, IQVIA Holdings has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' ROE % Adjusted to Book Value compare to WAT and ILMN?
IQVIA Holdings' ROE % Adjusted to Book Value of 3.81% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current ROE % Adjusted to Book Value is 3.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €218.53, compared to a current price of €169.40 — trading 22.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.81%. IQVIA Holdings' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current ROE % Adjusted to Book Value is 3.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of €169.40 is trading 22.5% below its estimated GF Value™ of €218.53.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for FRA:QTS:
ROE % Adjusted to Book Value: 3.81%
GF Value™: €218.53 vs. price of €169.40 (22.5% below fair value)
No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
90GF Score
Get the complete analysis for FRA:QTS
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QTS has been successfully added to your 
